サンプル依頼リスト カート
  • English
  • Korean
表紙：生殖補助医療技術の世界市場-2023年～2030年
市場調査レポート
商品コード
1316263

生殖補助医療技術の世界市場-2023年～2030年

Global Assisted Reproductive Technology Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
生殖補助医療技術の世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の生殖補助医療技術市場は、2022年に338億米ドルに達し、2030年には537億米ドルに達するなど、有利な成長が見込まれています。世界の生殖補助医療技術市場は、予測期間中（2023～2030年）に6.1%のCAGRを示すと予測されています。

生殖補助医療（ART）は生殖医療の進歩を促進し、不妊治療の成功率、安全性、効率の向上につながります。継続的な研究と技術開発は、不妊症のより良い理解と管理に貢献しています。その結果、この分野は進化を続け、生殖補助を求める個人やカップルに革新的な解決策や治療オプションを提供しています。

市場力学

主要企業による戦略が市場成長を後押し

主要企業による戦略は、市場成長の促進に役立っています。例えば、2021年1月5日、女性医療ソリューションの著名なプロバイダーであるCooperSurgical社は、クリニックや患者向けの凍結保存ソフトウェアの有名なプロバイダーであるEmbryo Options社を買収しました。この買収により、CooperSurgicalの画期的な生殖治療のラインナップが拡充されました。

エンブリオ・オプションズと提携するクリニックは、凍結保存された胚、卵子、精子の自動請求と合理化された管理から恩恵を受け、回収の増加、検体放棄の減少、凍結在庫管理コストの削減につながります。

シングルペアレントの増加が市場成長を促進する

シングルペアレントの増加、同性婚や生殖補助医療技術に対する意識の高まりは、予測期間を通じてART市場の成長に重要な影響を及ぼすとみられます。

例えば、ヒューマン・ライツ・キャンペーン（HRC）財団の2022年報告書によると、同性婚が合法である国の数は2022年には32カ国に上り、いくつかの国で議会や裁判の手続きが始まっており、このグラフはさらに上昇すると予想されています。同性婚の増加の結果、ART治療に対する需要は劇的に増加し、市場の成長を後押しすると予測されています。

生殖補助医療システムの高コストが市場成長を妨げる

ART治療には、精子や卵子の回収、受精、胚培養、凍結保存などの実験室作業が含まれます。これらのラボサービスに必要な専門機器、消耗品、専門知識はコストの一因となります。さらに、凍結胚や配偶子の長期保存には、メンテナンスや保管施設に継続的な費用がかかります。

ARTの技術や技法の進歩には、継続的な研究開発が必要です。生殖医療分野における調査研究、臨床試験、技術革新の実施にかかる費用は、ARTシステムの費用全体に反映されています。

COVID-19影響分析

パンデミックの間、多くのARTクリニックは、封鎖、社会的遠ざけ方、ヘルスケアシステムの過負荷のため、一時的にサービスを中断または制限せざるを得なかっています。この混乱は、個人やカップルの不妊治療の延期やキャンセルにつながり、精神的にも物流的にも大きな課題を引き起こしました。

パンデミックにより、不妊治療に関する評価や診断を受けることが困難になっています。必要でない診療の予約や処置が延期されたりキャンセルされたりすることが多く、不妊症の問題の特定や対処が遅れることになっています。このような診断と治療の遅れは、多くの個人とカップルの親になるまでの道のりをさらに長引かせた。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、この地域の主要な市場プレーヤーの数が少ないことから、世界の生殖補助医療技術市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、生殖補助医療技術の世界市場の成長にほとんど影響を与えないと予想されます。

人工知能の影響分析

AIは着床前遺伝学的検査（PGT）と併用することで、胚からの遺伝子および染色体データを分析することができます。AIアルゴリズムは、特定の遺伝子マーカーと胚の生存能力との間のパターンと相関関係を特定することができ、着床成功の可能性を予測し、子孫の遺伝的障害のリスクを低減するのに役立ちます。AIはARTシステムを改善する上で大きな可能性を秘めているが、常にヘルスケア専門家の専門知識と指導のもとで使用されるべきであることに留意することが重要です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 不妊率の恒常的な上昇
      • ART成功率の向上
    • 抑制要因
      • 生殖補助医療システムの高コスト
    • 機会
      • ARTにより、個人やカップルが生殖に関する選択をより自由にコントロールできるようになる。
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 技術タイプ別

  • 体外受精（IVF）
  • 人工授精（AI-IUI）
  • 凍結胚交換（FER）
  • その他

第8章 手技別

  • 新鮮ドナー
  • 新鮮非ドナー
  • 凍結ドナー
  • 凍結非ドナー
  • 胚バンク

第9章 エンドユーザー別

  • 病院
  • 不妊治療クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別ダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Irvine Scientific（FUJIFILM Corporation）
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • CooperSurgical Inc
  • Thermo Fisher Scientific, Inc.
  • Genea Biomedx
  • Microm UK Ltd
  • Hamilton Thorne Inc
  • Merck KGaA
  • Laboratoire CCD
  • Vitrolife AB
  • OvaScience Inc.

第13章 付録

目次
Product Code: MD1496

Market Overview

The global assisted reproductive technology market reached US$ 33.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 53.7 billion by 2030. The global assisted reproductive technology market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030).

Assisted Reproductive Technology (ART) drives advancements in reproductive medicine, leading to improved success rates, safety, and efficiency of fertility treatments. Ongoing research and technological developments contribute to better understanding and management of infertility. As a result, the field continues to evolve, offering innovative solutions and treatment options to individuals and couples seeking reproductive assistance.

Market Dynamics

The Key Strategies by the Key Players Helps to Drive Market Growth

The key strategies by the key players helps to drive market growth. For instance, on January 5, 2021, CooperSurgical, a prominent provider of women's health care solutions, has acquired Embryo Options, a well-known provider of cryo-storage software for clinics and patients. CooperSurgical's full array of breakthrough reproductive treatments has been expanded with this acquisition.

Clinics that work with Embryo Options benefit from automated billing and streamlined management of cryo-preserved embryos, eggs, and sperm, which leads to increased collections, lower specimen abandonment, and lower cryo-inventory management costs.

The Rising Number of Single Parenting will Drive the Market Growth

The growing number of single parents, as well as increased awareness of same-sex weddings and assisted reproductive technologies, are likely to play a key influence in the growth of the ART market throughout the forecast period.

For instance, according to the Human Rights Campaign (HRC) Foundation's 2022 report, the number of nations where same-sex marriage is legal has climbed to 32 in 2022, with parliamentary or court processes beginning in several countries, and this graph is anticipated to rise further. As a result of the increase in same-sex marriages, demand for ART treatments is predicted to rise dramatically, boosting growth in the maket.

High Cost of Assisted Reproductive Technology Systems will Hamper the Market Growth

ART procedures involve laboratory work, including sperm and egg retrieval, fertilization, embryo culture, and cryopreservation. The specialized equipment, consumables, and expertise required for these laboratory services contribute to the cost. Additionally, long-term storage of frozen embryos or gametes incurs ongoing fees for maintenance and storage facilities.

Advancements in ART techniques and technologies require ongoing research and development. The cost of conducting research studies, clinical trials, and innovation in the field of reproductive medicine is reflected in the overall expense of ART systems.

COVID-19 Impact Analysis

Many ART clinics had to temporarily suspend or limit their services during the pandemic due to lockdowns, social distancing measures, and overwhelmed healthcare systems. This disruption led to the postponement or cancellation of fertility treatments for individuals and couples, causing significant emotional and logistical challenges.

The pandemic made it difficult for individuals to undergo fertility evaluations and diagnostic tests. Non-essential medical appointments and procedures were often postponed or canceled, leading to delays in identifying and addressing fertility issues. This delay in diagnosis and treatment further prolonged the journey to parenthood for many individuals and couples.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global assisted reproductive technology market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global assisted reproductive technology market growth over the forecast period.

Artificial Intelligence Impact Analysis

AI can be used in conjunction with preimplantation genetic testing (PGT) to analyze genetic and chromosomal data from embryos. AI algorithms can identify patterns and correlations between specific genetic markers and embryo viability, helping predict the likelihood of successful implantation and reducing the risk of genetic disorders in offspring. It is important to note that while AI holds great potential in improving ART systems, it should always be used in conjunction with the expertise and guidance of healthcare professionals.

Segment Analysis

The global assisted reproductive technology market is segmented based on technology type, procedure, end user and region.

The In-Vitro Fertilization Accounted for Approximately 53.2% of the Assisted Reproductive Technology Market Share

The ultimate benefit of IVF is a successful pregnancy and a healthy baby. IVF can make this a reality for people who might otherwise be unable to conceive a child. IVF gives women with blocked or damaged fallopian tubes the best chance of producing a child using their own eggs. Furthermore, new product releases and approvals by companies contribute to the segment's growth.

For instance, October. 25, 2022, TMRW Life Sciences, Inc. (TMRW), the company that invented of the world's first automated specimen management platform for frozen eggs and embryos used in in vitro fertilisation (IVF), has announced the opening of the world's most advanced fertility specimen cryostorage facility.

This technologically advanced facility in New York provides a new standard of care directly to patients and fertility clinic partners for the first time, delivering unparalleled levels of transparency into the safety of frozen eggs and embryos at the heart of practically every IVF experience. As a result, the aforementioned elements contribute to segment growth.

Geographical Analysis

North America Accounted for Approximately 43.4% of the Market Share

North America is expected to hold a significant market share in the global assisted reproductive technology market over the forecast period, owing to factors such as rising infertility in the region and public-sector initiatives that are expected to boost market growth over the forecast period.

For instance, infertility is on the rise. Infertile couples are using assisted reproductive technology (ART) at a rate of 5% to 10% each year. According to the United Nations, there were five children for every woman in the globe in 1950. In 2020, there will be two children for every woman on the planet.

In the United States, there has been a long-term reduction in birth and fertility rates, which has been linked to a variety of causes such as women's increased education and professional options, later marriage, improved access to contraception, delayed childbirth, and smaller family size. As a result, infertility rates are rising, which aids regional growth.

Competitive Landscape

The major global players in the assisted reproductive technology market are: Irvine Scientific (FUJIFILM Corporation), CooperSurgical Inc, Thermo Fisher Scientific, Inc., Genea Biomedx, Microm UK Ltd, Hamilton Thorne Inc, Merck KGaA, Laboratoire CCD, Vitrolife AB, OvaScience Inc among others.

Why Purchase the Report?

  • To visualize the global assisted reproductive technology market segmentation based on technology type, procedure, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of assisted reproductive technology market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global assisted reproductive technology market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Technology Type
  • 3.2. Snippet by Procedure
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The constant rise in the infertility rate
      • 4.1.1.2. Improving ART success rates
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of assisted reproductive technology systems
    • 4.1.3. Opportunity
      • 4.1.3.1. ART allows individuals and couples to have greater control over their reproductive choices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Technology Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 7.1.2. Market Attractiveness Index, By Technology Type
  • 7.2. In Vitro-fertilization (IVF) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Artificial Insemination (AI-IUI)
  • 7.4. Frozen Embryo Replacement (FER)
  • 7.5. Others

8. By Procedure

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 8.1.2. Market Attractiveness Index, By Procedure
  • 8.2. Fresh donor *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Fresh non-donor
  • 8.4. Frozen donor
  • 8.5. Frozen non-donor
  • 8.6. Embryo banking

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospital *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Fertility Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Plan Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Irvine Scientific (FUJIFILM Corporation) *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. CooperSurgical Inc
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Genea Biomedx
  • 12.5. Microm UK Ltd
  • 12.6. Hamilton Thorne Inc
  • 12.7. Merck KGaA
  • 12.8. Laboratoire CCD
  • 12.9. Vitrolife AB
  • 12.10. OvaScience Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us